EPS: As of FY2025 Q2, the actual value is USD 8.21.EBIT: As of FY2025 Q2, the actual value is USD -4.235 M.<h3>Segment Revenue</h3><ul><li>Research and Development Expenses: $1,608,000 for the six months ended June 30, 2025, compared to $1,727,000 for the same period in 2024, a decrease of 5.9%.</li><li>General and Administrative Expenses: $2,326,000 for the six months ended June 30, 2025, compared to $908,000 for the same period in 2024, an increase of 155.6%.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $4,238,000 for the six months ended June 30, 2025, compared to $2,912,000 for the same period in 2024, an increase of 44.8%.</li><li>Operating Loss: $3,934,000 for the six months ended June 30, 2025, compared to $2,635,000 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $4,960,000 for the six months ended June 30, 2025, compared to - $2,817,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $7,237,000 for the six months ended June 30, 2025, compared to $0 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue investing in the development of SIL204, including applying for Orphan Drug Designation, conducting toxicological studies, and initiating clinical trials. The company also aims to expand its intellectual property portfolio and hire additional personnel to support its operations.</li><li>Non-Core Business: The company is exploring additional product candidates to add to its pipeline and is seeking to increase its authorized share capital to support future financing activities.</li></ul>

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD 8.21